Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ali Tafreshi

Showing results (51-60 of 55) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 55 results.
Clinical Lung Cancer|March 25, 2022
Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Patients With Advanced Non-Squamous Non-Small Cell Lung CancerRamaswamy Govindan, Mike Lind, Amelia Insa, et al.
The New England Journal of Medicine|October 4, 2018
Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung CancerLuis Paz-Ares, Alexander Luft, David Vicente, et al.
European Urology|December 17, 2022
Corrigendum to "Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study" [Eur Urol 83 (2023) 15-26]Evan Y Yu, Josep M Piulats, Gwenaelle Gravis, et al.
European Urology|September 2, 2022
Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A StudyEvan Y Yu, Josep M Piulats, Gwenaelle Gravis, et al.
Cell|February 24, 2018
Identifying Medical Diagnoses and Treatable Diseases by Image-Based Deep LearningDaniel S Kermany, Michael Goldbaum, Wenjia Cai, et al.
Pageof 6

Showing results (51-60 of 55) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 55 results.
Clinical Lung Cancer|March 25, 2022
Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Patients With Advanced Non-Squamous Non-Small Cell Lung CancerRamaswamy Govindan, Mike Lind, Amelia Insa, et al.
The New England Journal of Medicine|October 4, 2018
Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung CancerLuis Paz-Ares, Alexander Luft, David Vicente, et al.
European Urology|December 17, 2022
Corrigendum to "Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study" [Eur Urol 83 (2023) 15-26]Evan Y Yu, Josep M Piulats, Gwenaelle Gravis, et al.
European Urology|September 2, 2022
Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A StudyEvan Y Yu, Josep M Piulats, Gwenaelle Gravis, et al.
Cell|February 24, 2018
Identifying Medical Diagnoses and Treatable Diseases by Image-Based Deep LearningDaniel S Kermany, Michael Goldbaum, Wenjia Cai, et al.
Pageof 6